Trial Profile
A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of VP-102 Topical Film Forming Solution [0.7% (w/v) in Subjects (2 Years and Older) With Molluscum Contagiosum
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Aug 2021
Price :
$35
*
At a glance
- Drugs Cantharidin (Primary)
- Indications Molluscum contagiosum
- Focus Therapeutic Use
- Acronyms Innovate
- Sponsors Verrica Pharmaceuticals
- 04 Mar 2021 According to a Verrica Pharmaceuticals media release, positive results from this study were published online in the January 2021 issue of the Journal of Drugs in Dermatology.
- 12 Feb 2019 According to a Verrica Pharmaceuticals media release, data from the study will be presented at the 2019 American Academy of Dermatology Annual Meeting.
- 12 Sep 2018 Results published in the Verrica Pharmaceuticals Media Release